Black Mold, Insects and Samples Poured Into Sinks: FDA Inspected Two Chinese Factories Supplying Compounded GLP-1 Ingredients

Black Mold, Insects and Samples Poured Into Sinks: FDA Inspected Two Chinese Factories Supplying Compounded GLP-1 Ingredients

Black Mold, Insects and Samples Poured Into Sinks: FDA Inspected Two Chinese Factories Supplying Compounded GLP-1 IngredientsDr. Kate Dee
Published on: 02/11/2026

FDA inspectors found black mold, insects and destroyed samples at two Chinese factories making semaglutide and tirzepatide ingredient for U.S. compounders.

compounded semaglutidecompounded tirzepatideGLP-1 active pharmaceutical ingredientFDA import alertImport Alert 66-80Import Alert 66-40Chengdu Shengnuo BiopharmNanjing Chengong PharmaceuticalChinese API suppliercompounding pharmacy503A pharmacycertificate of analysismedspa GLP-1weight loss clinic complianceMedSpa Board
Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.

Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.

Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.Dr. Kate Dee
Published on: 21/10/2026

An FDA peptide compounding policy is under review. It is not approval. What medspas need to know about BPC-157, enforcement discretion, and prescriber risk.

FDA peptidespeptide interim access policycompounded peptidesBPC-157BPC-157 legalpeptide therapy medspaenforcement discretion503A bulks listTB-500research use only peptidespeptide safetycompounding pharmacymedspa complianceunapproved drugsMedSpa Board